windtree therapeutics, inc. is a biotechnology company focused on developing novel kl4 surfactant therapies for respiratory diseases and other potential applications. windtree’s proprietary technology platform includes a synthetic, peptide-containing surfactant (kl4 surfactant ) that is structurally similar to human pulmonary surfactant — and novel drug-delivery technologies that are being developed to enable noninvasive administration of aerosolized kl4 surfactant. windtree is focused initially on improving the management of respiratory distress syndrome (rds) in premature infants as surfactant therapy has been shown to save lives in this condition. windtree believes that its proprietary technologies may make it possible, over time, to develop a pipeline of kl4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies and, in doing so, potentially deliver a lifetime of hope to patients and their families.
Company profile
Ticker
WINT
Exchange
Website
CEO
Craig E. Fraser
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ANSAN INC, ANSAN PHARMACEUTICALS INC, DISCOVERY LABORATORIES INC /DE/
SEC CIK
Corporate docs
IRS number
943171943
WINT stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
12 Mar 24
8-K
Departure of Directors or Certain Officers
16 Feb 24
S-3
Shelf registration
14 Feb 24
PRE 14A
Preliminary proxy
12 Feb 24
8-K
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
31 Jan 24
8-K
Entry into a Material Definitive Agreement
25 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Jan 24
8-K
Entry into a Material Definitive Agreement
17 Jan 24
424B5
Prospectus supplement for primary offering
16 Jan 24
8-K
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
9 Nov 23
Latest ownership filings
SC 13G/A
Lincoln Park Capital Fund, LLC
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G
Flynn James E
1 Feb 24
SC 13G
Duvvuri Krishna
13 Nov 23
4
Craig Fraser
28 Sep 23
4
Craig Fraser
27 Sep 23
3
Jamie McAndrew
5 Sep 23
4
Daniel E. Geffken
29 Aug 23
4
Leslie J. Williams
25 Aug 23
4
Mark Strobeck
25 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.37 mm | 7.37 mm | 7.37 mm | 7.37 mm | 7.37 mm | 7.37 mm |
Cash burn (monthly) | 1.37 mm | 89.25 k | 1.56 mm | 2.22 mm | 1.28 mm | 1.10 mm |
Cash used (since last report) | 8.14 mm | 531.38 k | 9.31 mm | 13.25 mm | 7.65 mm | 6.57 mm |
Cash remaining | -775.93 k | 6.83 mm | -1.94 mm | -5.88 mm | -283.74 k | 790.93 k |
Runway (months of cash) | -0.6 | 76.6 | -1.2 | -2.6 | -0.2 | 0.7 |
Institutional ownership, Q3 2023
30.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 14 |
Opened positions | 4 |
Closed positions | 4 |
Increased positions | 3 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 201.80 mm |
Total shares | 2.75 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Center Laboratories | 1.54 mm | $2.19 mm |
Lind Global Fund II | 475.10 k | $1.01 mm |
Lincoln Park Capital Fund | 459.04 k | $1.09 mm |
Alyeska Investment | 136.52 k | $129.50 mm |
Huang James | 68.98 k | $0.00 |
Vanguard | 41.64 k | $39.50 mm |
Geode Capital Management | 14.20 k | $13.69 mm |
Tower Research Capital | 9.67 k | $9.18 mm |
UBS UBS Group AG - Registered Shares | 5.91 k | $5.61 mm |
WFC Wells Fargo & Co. | 30.00 | $28.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Sep 23 | Fraser Craig | Common Stock | Buy | Acquire P | No | No | 1.0199 | 2,500 | 2.55 k | 57,877 |
26 Sep 23 | Fraser Craig | Common Stock | Buy | Acquire P | No | No | 0.9 | 2,500 | 2.25 k | 55,377 |
23 Aug 23 | Fraser Craig | Common Stock | Grant | Acquire A | No | No | 0 | 45,867 | 0.00 | 52,877 |
23 Aug 23 | Fraser Craig | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.21 | 68,800 | 83.25 k | 68,800 |
23 Aug 23 | Eric Curtis | Common Stock | Grant | Acquire A | No | No | 0 | 14,667 | 0.00 | 15,920 |
23 Aug 23 | Eric Curtis | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.21 | 22,000 | 26.62 k | 22,000 |
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
2 Feb 24
Windtree Therapeutics Eliminates $15M Contingent Liability To Deerfield Management Company
26 Jan 24
12 Health Care Stocks Moving In Thursday's After-Market Session
25 Jan 24
Windtree Eliminates $15M Contingent Liability To Deerfield Management Company
25 Jan 24
12 Health Care Stocks Moving In Friday's After-Market Session
19 Jan 24
Press releases
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
1 Feb 24
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
31 Jan 24
Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
26 Jan 24
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
25 Jan 24
Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China
18 Jan 24